Tirzepatide received FDA approval as Mounjaro (type 2 diabetes) in May 2023 and as Zepbound (obesity) in November 2023
[13] Trials for obesity [edit] In March 2021, in a phase III randomized, double-blind trial, 1,961 adults with a body mass index of 30 or greater were assigned in a 2:1 ratio to a treatment with once-weekly subcutaneous semaglutide or placebo, plus lifestyle intervention
Another benefit is the dosing flexibility
The researchers included 30 obese patients in a randomized, double-blind, placebo-controlled, two-period crossover experiment over a 12-week period to accomplish this
This 20mg research vial supports laboratory investigation of incretin receptor pharmacology, multi-agonist metabolic signalling, and adipose tissue biology
Errors related to compounded semaglutide dose miscalculations FDA-approved injectable semaglutide products are dosed in milligrams, have standard concentrations and are currently only available in pre-filled pens